In addition, as JAK/STAT3 mutations promoted STAT3-based transcription activation and directly regulated NF-κB and CD30 levels in NIK+/ALK- ALCL, combined NIK and JAK inhibitor therapy could be applied to benefit patients [165]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.